KEY ROLE OF HOSPITAL PHARMACY IN A NON-PROFIT STUDY INVOLVING RUXOLITINIB 5mg CPS: IMPLEMENTATION AND QUALITY ASSURANCE OF AN INVESTIGATIONAL MANUFACTURING PRODUCT
3PC-066
COMPOUNDING AN EYE DROP FORMULATION OF TOPICAL INSULIN FOR CORNEAL DEFECTS REFRACTORY TO PREVIOUS TREATMENT: EXPERIENCE IN REAL CLINICAL PRACTICE
3PC-065
IMPACT OF LIGHT STRESS ON THE ISOFORM PROFILE OF NIVOLUMAB (OPDIVO) IN OPENED VIALS ESTIMATED BY (RP)UHPLC-UV-(HESI/ORBITRAP)-MS
3PC-064
A MULTICENTRE STUDY COMPARING CHEMOTHERAPY PREPARATIONS USING A DIGITAL VIDEO MONITORING
3PC-063
PERFORMANCE QUALIFICATION OF ROBOTIC SYSTEM FOR CYTOTOXIC DRUG PREPARATION IN A FULLY GMP COMPLIANT HOSPITAL PHARMACY
3PC-062
IMPACT OF THE PREPARATION OF THE 1.0 MG/ML NIVOLUMAB CLINICAL SOLUTION ON THE PARTICULATES (AGGREGATION) MEASURED BY DYNAMIC LIGHT SCATTERING: NaCl AND GLUCOSE CONCENTRATION AND AGITATION EFFECT
3PC-061
PHYSICOCHEMICAL STABILITY OF CLOXACILLIN SOLUTION IN POLYPROPYLENE SYRINGES AT 125 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER
3PC-060
PHYSICOCHEMICAL STABILITY OF VANCOMYCIN SOLUTION IN ELASTOMERIC DEVICES AT 37.5 MG/ML IN 0.9% SODIUM CHLORIDE AND DEXTROSE 5% IN WATER
3PC-059
PHYSICOCHEMICAL STABILITY OF CEFTOLOZANE/TAZOBACTAM IN POLYPROPYLENE SYRINGES AT 61.5/31.25 mg/mL AND IN ELASTOMERIC DEVICES AT 25.0/12.5 mg/mL
3PC-058
PHYSICOCHEMICAL STABILITY OF MEROPENEM IN POLYPROPYLENE SYRINGES AT 41.7 mg/mL FOR INTENSIVE CARE UNITS
3PC-055
STABILITY OF UROKINASE IN CITRATE BASED SOLUTIONS
3PC-056
A STABLE READY-TO-USE FORMULATION OF PHENYLEPHRINE HCL IN SYRINGES
3PC-057
USING DIFFERENT TECHNIQUES TO PREPARE ORODISPERSIBLE FILMS IN A HOSPITAL PHARMACY
3PC-054
SODIUM BENZOATE SUSPENSION IN NON-KETOTIC HYPERGLYCINAEMIA: A CASE REPORT (submitted in 2019)
3PC-053
IMPACT OF SERIALISATION ON RECEPTION OF MEDICINES AND ACTIVITY SMOOTHING (submitted in 2019)
